Company profile
ZEVRA THERAPEUTICS, INC.
NASDAQ:ZVRABiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MIPLYFFA | approved | $30.2MQ2 2026 | 0 | — |
| APADAZ | approved | — | 78 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02612129 | phase2_3 | completed | 2016-06-14 | 2018-06-25 | ZevraDenmark | Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C |
| NCT03491462 | phase3 | completed | 2018-07-31 | 2020-12-18 | ZevraDenmark | Arimoclomol in Amyotropic Lateral Sclerosis |
| NCT03836716 | phase3 | terminated | 2019-09-19 | 2021-07-02 | ZevraDenmark | Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial |
| NCT04049097 | phase3 | terminated | 2019-05-20 | 2021-11-15 | ZevraDenmark | Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial |
| NCT03292952 | phase3 | completed | 2017-12-20 | 2018-05-16 | Zevra Therapeutics | KP415 Classroom Study in Children (6-12 Years of Age) With ADHD |
FDA applications (2)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 214927 | 2024-09-20 | NDA | ZEVRA DENMARK AS | |||||
Loading… | ||||||||
| NDA 208653 | 2018-02-23 | NDA | ZEVRA THERAPEUTICS | |||||
Loading… | ||||||||